March 2026
LSD
What March 2026's 7 new studies found, synthesized from the papers below. All LSD research →
The synthesis
Synthesized from 7 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for LSD, lysergic acid diethylamide, lysergide, then ranked by relevance.
Research in March 2026 indicates that LSD alters human brain dynamics by decoupling low-frequency activity from anatomical constraints and reorganizing high-frequency gamma activity, with gamma-band changes predicting ego dissolution. Low doses of LSD (13 and 26 µg) also produced significant, measurable subjective effects in healthy volunteers. However, national data showed a decline in past-year LSD use in the US between 2021 and 2023, and its therapeutic potential in areas like adolescent mental health, palliative care, and opioid use disorder remains largely under investigation or lacks clear positive findings from the provided studies.
Confidence in the evidence
Low-Moderate- The evidence base includes diverse study types (animal, human experimental, observational, reviews) addressing different aspects of LSD, rather than converging on a single therapeutic outcome.
- Specific findings on brain dynamics and subjective effects at low doses are reported from human studies, but therapeutic efficacy in clinical populations is primarily discussed as an area for future research.
- Sample sizes for some human experimental studies are not specified, and an animal study did not clearly demonstrate a positive therapeutic effect for opioid use disorder.
- The overall picture is fragmented, with no large-scale, consistent evidence for a specific therapeutic application across multiple well-controlled human trials.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Effects of Psychedelics Lysergic Acid Diethylamide and R (–)-2,5-Dimethoxy-4-Iodoamphetamine on Oral Opioid Consumption and Naloxone-Precipitated Withdrawal in Male C57Bl/6J Mice 2026 | animal study | Unclear | Mice consuming fentanyl analogs defended their consumption despite bitter taste after a single treatment with LSD, suggesting no clear positive effect on reducing opioid consumption defense in this model. | |
| Classic psychedelic medicines for adolescent refractory mental health disease 2026 | commentary/review | Unclear | This commentary notes classic psychedelics, including LSD, have shown strong efficacy in adults but highlights that adolescents are excluded from clinical trials, advocating for cautious, ethically grounded research in this population. | |
| The renaissance of research on psychedelics in child and adolescent psychopharmacology 2026 | review | Unclear | This review examines the rationale for investigating classic serotonergic psychedelics, including LSD, in pediatric psychopharmacology, noting ongoing trials primarily involve adolescents aged 16+ and cautioning due to developmental vulnerabilities. | |
| LSD Relaxes Structural Constraints on Brain Dynamics and Default Mode Decoupling Tracks Ego Dissolution 2026 | human study | Supports | LSD induces a robust decoupling of low-frequency activity from anatomical constraints and selective reorganization of high-frequency gamma activity, with greater gamma-band decoupling predicting ego dissolution intensity. | |
| Meaning and Psychedelics in Palliative Care: A Narrative Review. 2026 | narrative review | Unclear | This review states that psychedelic therapies, including implicitly LSD, are under investigation for existential distress in palliative care, with meaning-making being a typical feature of such therapies. | |
| Hallucinogen use in the United States, 2021-2023: Diverging trends and subgroup patterns. 2026 | observational | Opposes | Past-year LSD use declined in the United States from 0.88% in 2021 to 0.58% in 2023, based on nationally representative data. | |
| m-DASC: Measuring Subjective Effects of Very Low Doses of Psychedelic Drugs. 2026 | controlled study | 199 | Supports | A new questionnaire (m-DASC) developed for low doses of psychedelics showed significant subjective effects of LSD at 26 and 13 µg doses in healthy volunteers. |
Mice consuming fentanyl analogs defended their consumption despite bitter taste after a single treatment with LSD, suggesting no clear positive effect on reducing opioid consumption defense in this model.
animal study
This commentary notes classic psychedelics, including LSD, have shown strong efficacy in adults but highlights that adolescents are excluded from clinical trials, advocating for cautious, ethically grounded research in this population.
commentary/review
This review examines the rationale for investigating classic serotonergic psychedelics, including LSD, in pediatric psychopharmacology, noting ongoing trials primarily involve adolescents aged 16+ and cautioning due to developmental vulnerabilities.
review
LSD induces a robust decoupling of low-frequency activity from anatomical constraints and selective reorganization of high-frequency gamma activity, with greater gamma-band decoupling predicting ego dissolution intensity.
human study
This review states that psychedelic therapies, including implicitly LSD, are under investigation for existential distress in palliative care, with meaning-making being a typical feature of such therapies.
narrative review
Past-year LSD use declined in the United States from 0.88% in 2021 to 0.58% in 2023, based on nationally representative data.
observational
A new questionnaire (m-DASC) developed for low doses of psychedelics showed significant subjective effects of LSD at 26 and 13 µg doses in healthy volunteers.
controlled study Sample size: 199
Points of agreement
- LSD has measurable effects on human brain dynamics and subjective experience, even at low doses.
- There is a recognized need for more controlled research on LSD's therapeutic potential in specific clinical populations, such as adolescents and palliative care patients.
Conflicts
- No direct conflicts were identified between the findings of the provided studies, as they address different aspects of LSD research.
Gaps
- Lack of direct human clinical trial data on LSD's therapeutic efficacy in adolescents with refractory mental health disorders.
- Limited evidence for LSD's efficacy in palliative care settings, with research still in early stages.
- The animal study on opioid use disorder did not clearly demonstrate a positive therapeutic effect for LSD.
- Durability of observed effects (e.g., brain dynamics, subjective effects) is not discussed in the provided abstracts.
- Specific populations (e.g., diverse age groups, specific patient populations beyond healthy volunteers) are understudied for LSD's effects and therapeutic potential.